Mannatide (Polyactin A)

• Product Detail

What is Mannatide?

The used name of Mannatide was Polyactin A. In 2000, China Drug Administration renamed Polyactin A to Mannatide. Mannatide is a white or yellowish, odorless, tasteless amorphous powder, chemically stable mixture with certain degree of homogeneity. There is no small molecular sugars like monosaccharide, disaccharide, etc and no amino acids. It is soluble in water, insoluble in organic solvents, composed entirely of Mannatide molecules with different chain lengths and the molecular mass is about 71 ku. The total sugar content in the Mannatide is 87.7% to 90.3%, mainly composed of mannose and a small amount of glucose residues. The total amino acid content is 4.5% to 6.2%, mainly composed of Aspartic acid, Threonine, Serine, Glutamic acid, Alanine and Leucine. There are two different kinds of bonds: N- glycosidic bond and O- glycosidic bond.

Benefits of Mannatide

1.Polyactin A (Mannatide ) and peptide-based cancer

>Polyactin A is a novel and potent immunological adjuvant for peptide-based cancer vaccine.

Wang W1, Li Y1, Wang Y1, Ren S2, Li Y3, Wang B2.

Abstract

Synthetic peptide cancer vaccines are poorly immunogenic sub-unit vaccines and thus essentially need adjuvants in their formulations to increase the efficacy by enhancing the peptide-specific immune response. However, aluminum-based compounds are almost dependent for clinical use at present. Therefore, the increasing use of peptide-based vaccines makes the need for novel and potent adjuvants. Polyactin A (PAA) has been used for the clinical treatment of impaired immunity in China for over 30years. To figure out the adjuvant effects of PAA for E75 peptide breast cancer vaccine (Her2 p369-p377), the generation of mature dendritic cells (DCs) from peripheral blood monocytes (PBMCs) cultured with PAA, IL-4 and TNF-α was assessed by morphologic features and the expressions of special surface markers using flow cytometry. Then the functional features of PBMCs-derived DCs cultured with PAA, IL-4 and TNF-α were investigated by inducing E75-specific cytotoxicity. Finally, C57BL/6-Tg(HLA-A2.1)1Enge/J transgenic mice were immunized with E75 and various amounts of PAA, and splenic lymphocyte proliferation and the IFN-γ level were determined. The results showed that PAA, just like granulocyte-macrophage colony stimulating factor, with IL-4 and TNF-α efficiently induced mature DCs from PBMCs, and these DCs could trigger a potent E75 peptide-specific CD8+ T-cell response in vitro. Immunization with E75 and PAA significantly increased positive rates of CD4+ and CD8+ T lymphocytes, and enhanced splenocytes proliferation and levels of IFN-γ in splenocytes when induced by E75. Our results indicated that PAA could efficiently induce E75-specific immunologic responses in vitro and in vivo. Therefore, PAA possesses potent adjuvant effect on peptide-based cancer vaccine. Our study provides a safe, effective and novel adjuvant for clinical use.

2.mannatide and immunological activity

>Structure elucidation and immunological activity of a novel glycopeptide from mannatide.

Shen Y1, Wu M1, Xu Z1, Wan Y2, Zhang L2, Zhang W1, Xia W3.

Abstract

A water-soluble glycopeptide, designated as MTW, was isolated and purified from crude mannatide by DEAE-Sepharose. MTW showed one symmetrical peak on HPGPC with an average molecular weight of 2.95×104Da. MTW contained 16 kinds of amino acids and the total amino acid content was 0.95%. The structure of polysaccharide moiety of MTW was elucidated based on monosaccharide composition, methylation analysis, partial acid hydrolysis, IR and 1D/2D NMR spectroscopy. The results showed that MTW was a homogeneous glycopeptide including mannose and glucose with a molar ratio of 2:1. The polysaccharide moiety of MTW had a backbone of (1→6)-α-d-Man p residues, which highly branched at O-2 position of (1→2,6)-α-d-Man p residues. The side chains were mainly composed of (1→)-α-d-Man p, (1→2)-α-d-Man p, (1→4)-α-d-Glc p, (1→4,6)-α-d-Glc p residues. The backbone of the polysaccharide moiety of MTW was the same as MT2-A (Li et al. [1]), which was the main component of mannatide, but the side chains of MTW were somewhat different from that of MT2-A. Complement-fixation test indicated that MTW had the same beneficial effect on immunological activity as MT2-A.

 3.Mannatide and Influenza

>Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59.

Ren ST1, Zhang XM2, Sun PF1,3, Sun LJ4, Guo X2, Tian T1, Zhang J1, Guo QY2, Li X2, Guo LJ5, Che J6, Wang B1,6, Zhang H7.

Abstract

Intranasal vaccination is more potent than parenteral injection for the prevention of influenza. However, because the poor efficiency of antigen uptake across the nasal mucosa is a key issue, immunostimulatory adjuvants are essential for intranasal vaccines. The immunomodulator mannatide or polyactin (PA) has been used for the clinical treatment of impaired immunity in China, but its adjuvant effect on an inactivated trivalent influenza vaccine (ITIV) via intranasal vaccination is unclear. To explore the adjuvant effect of PA, an inactivated trivalent influenza virus with or without PA or MF59 was instilled intranasally once a week in BALB/c mice. Humoral immunity was assessed by both the ELISA and hemagglutination inhibition (HI) methods using antigen-specific antibodies. Splenic lymphocyte proliferation and the IFN-γ level were measured to evaluate cell-mediated immunity. The post-vaccination serum HI antibody geometric mean titers (GMTs) for the H1N1 and H3N2 strains, antigen-specific serum IgG and IgA GMTs, mucosal SIgA GMT, splenic lymphocyte proliferation, and IFN-γ were significantly increased in the high-dose PA-adjuvanted vaccine group. The seroconversion rate and the mucosal response for the H3N2 strain were significantly elevated after high-dose PA administration. These adjuvant effects of high-dose PA for the influenza vaccine were comparable with those of the MF59 adjuvant, and abnormal signs or pathological changes were not found in the evaluated organs. In conclusion, PA is a novel mucosal adjuvant for intranasal vaccination with the ITIV that has safe and effective mucosal adjuvanticity in mice and successfully induces both serum and mucosal antibody responses and a cell-mediated response.

4.Mannatide and malignant pleural effusions

>Efficacy of mannatide combined with sodium cantharidate vitamin B6 in the treatment of malignant pleural effusions.

Wang LZ1, Zhang HJ, Song J.

Chemoradiotherapy Center, Chengde Central Hospital, Hebei province, China

Abstract

OBJECTIVE:

To evaluate the efficacy of mannatide combined with sodium cantharidate vitamin B6 in the treatment of malignant pleural effusions.

MATERIALS AND METHODS:

Data for 69 patients with malignant pleural effusions who did not receive systemic chemotherapy were collected. Injection into the thorax using mannatide combined with sodium cantharidate vitamin B6 was performed for 37 patients in the experimental group and mannatide combined with cisplatin for 32 patients in the control group. Objective responses, KPS (Karnofsky Scoring) and incidences of side effects between the two groups were compared.

RESULTS:

13 patients reached CR (complete response) and 11 PR (partial response) in the experimental group, while 12 patients reached CR and 9 PR in the control group, the difference in overall objective responses between the two groups not being significant (66.7% vs 63.6%, p=0.806). However, improvement of KPS in the experimental group was greater than in the control group; total side-effect incidences during the period of treatment were 22.2% (8/36) and 54.5% (18/33), respectively (p=0.006).

CONCLUSIONS:

Regimen of mannatide combined with sodium cantharidate vitamin B6 had better improvement in quality-of-life and symptom relief, with a lower side-effect incidence in treatment of malignant pleural effusions.

5.Polyactin A (Mannatide ) and HIV

Polyactin A increases CD4(+) T-cell counts in HIV-infected individuals with insufficient immunologic response to highly active antiretroviral therapy.

Su QJ1, Li YZ, Liang FL, Xiao J, Deng X.

Center for AIDS Research, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, Guangxi, PR China.

Abstract

We conducted a study to determine whether an immunomodulator, polyactin A, is able to enhance the immunologic response in patients with insufficient immunologic response to highly active antiretroviral therapy. From 783 patients, 48 were eligible and were randomly assigned to an experimental group receiving polyactin A for 3 months or a control group. CD4(+) T-cell counts in the experimental group increased from 201 ± 31 to 228 ± 38 cells/µl after treatment (p < 0.001). CD4(+) T-cell counts in the control group and CD8(+) T-cell counts and CD4(+)/CD8(+) ratios in both groups did not differ significantly between baseline and month 3. The experimental group had a higher CD4(+) T-cell count than the control group at month 3 (228 ± 38 versus 205 ± 35, p < 0.05). Our work demonstrated that polyactin A can increase CD4(+) T-cell counts in patients with insufficient immunologic response to highly active antiretroviral therapy, but further studies are required to determine its clinical benefits.

Side effects and safety of Mannatide

Has not yet been reported that he has serious side effects.

Mannatide appears to have few side effects when used properly for short periods of time.

Pregnant and breastfeeding women should not take Mannatide.

Dosage of Mannatide supplement:

A typical dose would be 5-10 mg at a time, taken three times a day.

Company Information:

Nutra Green is a professional manufacturer and supplier of  Mannatide for the industry of bodybuilding,  dietary supplements, and sports nutriton ingredients. We guarantee you the best raw materials via breaktrough technology and customer service.